Author: admin

DelveInsight’s “Obesity Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.

Download DelveInsight’s comprehensive Obesity Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

Key Takeaways from the Obesity Pipeline Report

• On May 01, 2026- Boehringer Ingelheim initiated a phase 3 study is open to adults who are at least 18 years old and have a body mass index (BMI) of 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems related to their weight or risks of cardiovascular disease can participate. Participants must have previously tried to lose weight by changing their diet.
• DelveInsight’s Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment.
• The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
• Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.

Access DelveInsight’s in-depth pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies

The Obesity Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Obesity Pipeline Report also highlights the unmet needs with respect to the Obesity.

Obesity Overview

Obesity is the excessive or abnormal accumulation of fat or adipose tissue in the body that impairs health via its association with the risk of development of diabetes mellitus, cardiovascular disease, hypertension, and hyperlipidemia. It is a significant public health epidemic which has progressively worsened over the past 50 years.

Obesity Emerging Drugs

• Survodutide: Zealand Pharma

Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity.

• Ecnoglutide: Sciwind Biosciences

Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity.

• CT-868: Carmot Therapeutics

CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868’s effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity.

• DD01: D&D Pharmatech

DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD).

Explore DelveInsight’s expert-driven report today! @ Obesity Unmet Needs

The Obesity pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
• Obesity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.

Obesity Companies

Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Obesity Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Obesity Therapies @ Obesity Market Drivers and Barriers, and Future Perspectives

Scope of the Obesity Pipeline Report

• Coverage- Global
• Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
• Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.
• Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive Obesity Pipeline Report @ Obesity Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Obesity Overview
4. Obesity Pipeline Therapeutics
5. Obesity Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Survodutide: Zealand Pharma
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. CT-868: Carmot Therapeutics
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. DD01: D&D Pharmatech
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Inactive Obesity Products
19. Obesity Key Companies
20. Obesity Key Products
21. Obesity Unmet Needs
22. Obesity Market Drivers
23. Obesity Market Barriers
24. Obesity: Future Perspectives and Conclusion
25. Obesity Analyst Views
26. Obesity Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/obesity-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Clinical Trial Ecosystem Strengthens with 80+ Companies Driving Next-Gen Oncology Innovations | DelveInsight

DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Chronic Kidney Disease Research @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight

Key Takeaways from the Chronic Kidney Disease Pipeline Report

• On May 01, 2026- Medical College of Wisconsin initiated a study aimed to analyze the immunogenicity of nanovalent human papillomavirus vaccination (GARDASIL 9) in post-solid-organ transplant patients. The study duration is anticipated to be 36 months. The expected duration of subject participation is 24 months. Immunocompromised populations are at greater risk of HPV infection. Quadrivalent HPV vaccination has been performed and lower titers of antibodies have been compared to published date in non-immunocompromised population (controls). The HPV9 vaccination titers have not been measured in the immunocompromised population to date.
• On May 01, 2026- Vifor Fresenius Medical Care Renal Pharma conducted a study is to evaluate the safety and tolerability, as assessed by incidence of AEs, of 0.5 μg/kg IV difelikefalin in adolescent participants on HD (3 times weekly) with moderate-to-severe pruritus over 12 weeks. Additionally, difelikefalin plasma concentrations (Cmax and Ctrough) after multiple administrations will be evaluated at a few selected time points and the efficacy of difelikefalin in improving itching and health-related QoL will be investigated as exploratory.
• DelveInsight’s Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Chronic Kidney Disease treatment.
• The leading Chronic Kidney Disease Companies such as AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.
• Promising Chronic Kidney Disease Pipeline Therapies such as roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.

Stay informed about the cutting-edge advancements in Chronic Kidney Disease treatments @ Chronic Kidney Disease Clinical Trials Assessment

Chronic Kidney Disease Overview

Chronic kidney disease (CKD) is characterized by the presence of kidney damage or an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m², persisting for 3 months or more. CKD involves a progressive loss of kidney function, often leading to the need for renal replacement therapy, such as dialysis or transplantation. It is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease.

Chronic Kidney Disease Emerging Drugs Profile

• Baxdrostat : AstraZeneca

Baxdrostat, a highly potent inhibitor of aldosterone synthase, exhibits greater selectivity for aldosterone synthase compared to existing ASIs. Initial studies in cynomolgus monkeys demonstrated its ability to decrease aldosterone production, prompting further investigation in humans. The mechanism of action of baxdrostat involves inhibiting the enzyme aldosterone synthase, which is responsible for the final step in aldosterone biosynthesis. By selectively blocking this enzyme, baxdrostat reduces aldosterone levels, leading to decreased sodium reabsorption and fluid retention, ultimately lowering blood pressure. The drug is currently being evaluated in the Phase III stage of development for the treatment of patients with CKD.

• Ziltivekimab: Novo Nordisk

Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). Ziltivekimab is being developed a therapy intended to reduce the risk of major cardiovascular adverse events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients who are diagnosed with moderate to severe CKD and have ASCVD and inflammation are at risk for an adverse cardiovascular event at a high rate and there are no approved therapies to prevent this risk. The proinflammatory cytokine, interleukin-6 (IL-6) has been shown to be an independent, causal factor of ASCVD with evidence generated from human genetic studies and preclinical studies. The drug is being evaluated in the Phase III stage of development to treat patients with moderate to severe chronic kidney disease.

• BI-685509: Boehringer Ingelheim

BI 685509 is a novel small soluble guanylate cyclase (sGC) molecule activator that exhibits an in vitro profile consistent with that of an sGC activator. BI 685509 reduced proteinuria and glomerulosclerosis in the ZSF1 rat, a model of diabetic kidney disease (DKD), and reduced tubulointerstitial fibrosis in a 7-day unilateral ureteral obstruction model in rats. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Kidney Disease.

• PXL770: Poxel SA

PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). Currently, the drug is in the Phase I stage of Clinical trial evaluation for the treatment of Autosomal Dominant Polycystic Kidney Disease.

• RGLS8429: Regulus Therapeutics

RGLS8429 is a novel, next-generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus’ first-generation compound. Currently, the drug is in Phase I for the treatment of Chronic Kidney Disease.

The Chronic Kidney Disease Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Kidney Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease Treatment.
• Chronic Kidney Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Kidney Disease market

Learn more about Chronic Kidney Disease Drugs opportunities in our groundbreaking Chronic Kidney Disease Research and development projects @ Chronic Kidney Disease Unmet Needs

Chronic Kidney Disease Companies

AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chronic Kidney Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Chronic Kidney Disease treatment by visiting our website @ Chronic Kidney Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Kidney Disease Pipeline Report

• Coverage- Global
• Chronic Kidney Disease Companies- AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.
• Chronic Kidney Disease Pipeline Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.
• Chronic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Chronic Kidney Disease Pipeline on our website @ Chronic Kidney Disease Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Kidney Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Kidney Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Baxdrostat: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. BI-685509: Boehringer Ingelheim
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RGLS8429: Regulus Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Kidney Disease Key Companies
21. Chronic Kidney Disease Key Products
22. Chronic Kidney Disease- Unmet Needs
23. Chronic Kidney Disease- Market Drivers and Barriers
24. Chronic Kidney Disease- Future Perspectives and Conclusion
25. Chronic Kidney Disease Analyst Views
26. Chronic Kidney Disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Kidney Disease Drug Development Pipeline Expands as 75+ Companies Focus on Novel Mechanisms of Action | DelveInsight

DelveInsight’s “Multiple System Atrophy Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It covers the Multiple System Atrophy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple System Atrophy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Multiple System Atrophy Pipeline? @ Multiple System Atrophy Pipeline Outlook Report

Key Takeaways from the Multiple System Atrophy Pipeline Report

• On May 01, 2026- AstraZeneca initiated a phase I/II study will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib in participants with metastatic prostate cancer. Additional combinations with other anticancer agents may be added via protocol amendment as separate modules. The study follows a modular design, allowing initial assessment of safety, tolerability, and preliminary efficacy across multiple treatment arms. Each Module has 2 parts: Part A (monotherapy dose escalation or combination dose finding) and Part B (monotherapy dose optimization and expansion or combination dose expansion). Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention occur.
• On April 30, 2026- Precision BioSciences Inc. conducted a Phase 1/2a trial is to evaluate the safety, tolerability, and preliminary efficacy of PBGENE-DMD in patients with DMD harboring mutations amenable to excision of exons 45-55. Given the limitations of existing therapeutic strategies, PBGENE-DMD represents a novel, innovative approach with the potential for a one-time, durable correction of the underlying genetic defect in the largest molecular subset of patients with DMD.
• On April 29, 2026- Dasher Neuroscience Inc. initiated a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
• On April 28, 2026- PepGen Inc. announced a phase 2 study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared to placebo.
• DelveInsight’s Multiple System Atrophy Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Multiple System Atrophy treatment.
• The leading Multiple System Atrophy Companies such as Cytora Ltd., Alterity Therapeutics, H. Lundbeck A/S, AskBio, Corestemchemon, Inc., Tiziana Life Sciences Ltd., Kainos Medicine Inc., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., ProMIS Neurosciences, Inc., Ionis Pharmaceuticals, Inc., and Yoda Therapeutics Inc. andothers.
• Promising Multiple System Atrophy Therapies such as TEV-56286, YA-101, Foralumab Nasal, Verdiperstat, TAK-341, ATH434, Safinamide Methanesulfonate, Rasagiline Mesylate, ONO-2808, AZD3241, and others.

Want to know which companies are leading innovation in Multiple System Atrophy? @ Multiple System Atrophy Clinical Trials Assessment

The Multiple System Atrophy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Multiple System Atrophy Pipeline Report also highlights the unmet needs with respect to the Multiple System Atrophy.

Multiple System Atrophy Overview

Multiple system atrophy (MSA) is a rare disease, affecting potentially 15,000 to 50,000 Americans, including people of all racial groups. The cause of MSA is unknown. The vast majority of cases are sporadic, meaning they occur at random. Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the central nervous system (which controls how a person moves), and the autonomic nervous system, which controls involuntary functions such as blood pressure or digestion.

Multiple System Atrophy Emerging Drugs Profile

• Amlenetug: H. Lundbeck A/S

Amlenetug (also known as Lu AF82422), developed by H. Lundbeck A/S, is an investigational human monoclonal antibody designed to target neurodegenerative processes in multiple system atrophy. The drug specifically binds to extracellular α-synuclein, a pathological protein implicated in MSA, with the aim of preventing its uptake into cells and inhibiting the seeding and spread of toxic protein aggregates across the brain, additionally, through its active Fc region, it may enhance immune-mediated clearance of α-synuclein via microglial activity, thereby potentially slowing disease progression. The drug has received several important designations, including FDA Fast Track designation (2025), Orphan Drug Designation in the US, EU, and Japan, and SAKIGAKE designation in Japan, highlighting its potential to address a significant unmet medical need. Currently, amlenetug is in Phase III clinical development, being evaluated in the global MASCOT trial (NCT06706622), a randomized, double-blind, placebo-controlled study assessing its efficacy, safety, and tolerability in patients with MSA, with dosing administered via intravenous infusion approximately every four weeks.

• ATH434: Alterity Therapeutics

ATH434, developed by Alterity Therapeutics, is an investigational oral small-molecule therapeutic designed to treat neurodegenerative diseases such as multiple system atrophy (MSA). The drug acts as an iron chaperone, targeting pathological processes by redistributing excess iron in the brain and inhibiting α-synuclein aggregation, which is a key driver of neurodegeneration in MSA, ATH434 aims to protect neurons and slow disease progression. ATH434 is being developed primarily for MSA, a rare and rapidly progressive neurodegenerative disorder with significant unmet medical need. The drug has received Orphan Drug Designation from the U.S. FDA and the European Commission, as well as FDA Fast Track designation, underscoring its potential clinical importance. Clinically, ATH434 has completed Phase II trials (ATH434-201/202), and based on positive data, the program is advancing toward Phase III development, positioning it as a late-stage asset in Alterity’s pipeline.

• hOMSC300: Cytora Ltd.

hOMSC300, developed by Cytora Ltd., is an investigational allogeneic, off-the-shelf cell therapy, a unique stem cell population derived from the neural crest with properties of neural, mesenchymal, and regenerative cells. These cells exhibit a dual mechanism of action involving cell replacement and paracrine trophic effects, enabling neuroprotection, regeneration, and modulation of neuroinflammation, which are key pathological processes in neurodegenerative diseases. The therapy is being developed for multiple system atrophy (MSA), a rare and progressive neurodegenerative disorder affecting autonomic and motor functions, and aims to act as a disease-modifying treatment by slowing disease progression and preserving neuronal function. From a clinical development perspective, Cytora’s pipeline clearly indicates that hOMSC300 is currently in Phase I clinical studies for MSA, with ongoing trials evaluating safety and preliminary efficacy following intrathecal administration.

• AB-1005: AskBio

AB-1005 is an investigational gene therapy developed by AskBio, a wholly owned subsidiary of Bayer AG. The therapy is based on an adeno-associated viral vector serotype 2 (AAV2) designed to deliver the gene encoding glial cell line-derived neurotrophic factor (GDNF) directly into the brain. Mechanistically, AB-1005 enables sustained local production of GDNF within targeted brain regions, which is intended to support the survival and function of dopaminergic neurons and enhance dopamine signaling, thereby addressing the underlying neurodegeneration. The therapy is currently being investigated in the Phase I stage of its development for the treatment of Multiple System Atrophy – parkinsonian type (MSA-P).

If you’re tracking ongoing Multiple System Atrophy Clinical trials, this press release is a must-read @ Multiple System Atrophy Treatment Drugs

The Multiple System Atrophy Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment.
• Multiple System Atrophy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market.

Multiple System Atrophy Companies

Cytora Ltd., Alterity Therapeutics, H. Lundbeck A/S, AskBio, Corestemchemon, Inc., Tiziana Life Sciences Ltd., Kainos Medicine Inc., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., ProMIS Neurosciences, Inc., Ionis Pharmaceuticals, Inc., and Yoda Therapeutics Inc. andothers.

Multiple System Atrophy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as,

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Multiple System Atrophy Products have been categorized under various Molecule types such as,

• Oligonucleotide
• Peptide
• Small molecule

From emerging drug candidates to competitive intelligence, the Multiple System Atrophy Pipeline Report @ Multiple System Atrophy Market Drivers and Barriers, and Future Perspectives

Scope of the Multiple System Atrophy Pipeline Report

• Coverage- Global
• Multiple System Atrophy Companies- Cytora Ltd., Alterity Therapeutics, H. Lundbeck A/S, AskBio, Corestemchemon, Inc., Tiziana Life Sciences Ltd., Kainos Medicine Inc., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., ProMIS Neurosciences, Inc., Ionis Pharmaceuticals, Inc., and Yoda Therapeutics Inc. and others.
• Multiple System Atrophy Therapies- TEV-56286, YA-101, Foralumab Nasal, Verdiperstat, TAK-341, ATH434, Safinamide Methanesulfonate, Rasagiline Mesylate, ONO-2808, AZD3241, and others.
• Multiple System Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Multiple System Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Multiple System Atrophy Treatment landscape in this detailed analysis @ Multiple System Atrophy Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Multiple System Atrophy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Multiple System Atrophy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. NASP: Swedish Orphan Biovitrum A
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. ABP-671: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PRX-115: Protalix Biotherapeutics Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Multiple System Atrophy Key Companies
21. Multiple System Atrophy Key Products
22. Multiple System Atrophy- Unmet Needs
23. Multiple System Atrophy- Market Drivers and Barriers
24. Multiple System Atrophy- Future Perspectives and Conclusion
25. Multiple System Atrophy Analyst Views
26. Multiple System Atrophy Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple System Atrophy Clinical Pipeline Intensifies with 20+ Industry Players Exploring Breakthrough Treatment Modalities | DelveInsight

DelveInsight’s “Triple Negative Breast Cancer Pipeline Insight 2026” report provides comprehensive insights about 165+ companies and 170+ pipeline drugs in the Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Triple Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Triple Negative Breast Cancer Treatment Landscape @ Triple Negative Breast Cancer Pipeline Outlook

Key Takeaways from the Triple Negative Breast Cancer Pipeline Report

• On May 01, 2026- Merck Sharp & Dohme LLC initiated a phase 3 study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician’s choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.
• On April 30, 2026- Gilead Sciences conducted a phase 3 study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician’s choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
• On April 29, 2026- Dana-Farber Cancer Institute initiated a research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative.
• On April 27, 2026- Memorial Sloan Kettering Cancer Center announced a phase 2 study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.
• On April 24, 2026- AstraZeneca conducted a phase IB/II study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
• DelveInsight’s Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 165+ active players working to develop 170+ pipeline treatment therapies.
• The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
• Promising Triple Negative Breast Cancer Pipeline Therapies such as Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.

Stay ahead with the most recent pipeline outlook for Triple Negative Breast Cancer @ Triple Negative Breast Cancer Treatment Drugs

Triple Negative Breast Cancer Overview

Triple Negative Breast Cancer (TNBC) is defined as a tumor where the estrogen and progesterone (ER/PR) are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers. TNBCs are frequently identified as hyper dense masses without associated calcifications. The majority of TNBCs are histologically classified as high-grade, invasive, ductal carcinomas of no special type with basal-like features. Central necrosis, pushing tumor borders, a conspicuous lymphocytic infiltrate, and fibrosis are common histologic features.

Triple Negative Breast Cancer Emerging Drugs

• Trilaciclib: G1 Therapeutics, Inc.

TofaciTrilaciclib, a transient IV-administered CDK4/6 inhibitor, is a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. This provides two potential benefits firstly bone marrow protection and therefore the immune system from damage caused by cytotoxic therapy, and secondly improved long term immune surveillance by upregulating the formation of certain memory T cells. Trilaciclib is being evaluated a number of tumor types and chemotherapy regimens to assess its potential myeloprotection, antitumor efficacy and safety in combination with cytotoxic therapies and other anticancer agents. Currently, the drug is in the Phase III stage of its development for the treatment of Triple Negative Breast Cancer.

• Olaparib: AstraZeneca

Olaparib is an oral PARP inhibitor developed by AstraZeneca, approved for BRCA-mutated triple-negative breast cancer (TNBC). It works by blocking PARP enzymes, preventing DNA repair in cancer cells, leading to cell death, particularly in BRCA1/2-mutant tumors. The OlympiAD trial showed that Olaparib significantly improved progression-free survival (PFS) compared to chemotherapy in metastatic TNBC. It is FDA-approved for germline BRCA-mutated, HER2-negative breast cancer and is being explored in combination with immunotherapy and chemotherapy for broader TNBC treatment. Currently, the drug is in the Phase II/III stage of its development for the treatment of Triple Negative Breast Cancer.

• Patritumab Deruxtecan: Daiichi Sankyo Company/Merck

Patritumab deruxtecan (HER3-DXd) is an investigational HER3-directed antibody–drug conjugate (ADC) developed by Daiichi Sankyo. It comprises a fully human anti-HER3 monoclonal antibody linked to a topoisomerase I inhibitor payload via a tumor-selective cleavable linker. HER3 is frequently overexpressed in triple-negative breast cancer (TNBC), correlating with poorer prognosis. In a phase 1/2 trial, patritumab deruxtecan demonstrated promising clinical activity in patients with HER3-expressing metastatic breast cancer. Currently, the drug is in the Phase II stage of its development for the treatment of Triple Negative Breast Cancer.

• NUV-868: Nuvation Bio Inc.

NUV-868 is an experimental drug being studied alone and in combination with PARP inhibitors for the treatment of advanced solid tumors, including triple-negative breast cancer (TNBC). Nuvation Bio had decided not to initiate a Phase II study of NUV-868 as a monotherapy or in combination with olaparib or enzalutamide in the advanced solid tumor indications that were part of the Phase I and Phase Ib study designs. The Company is evaluating next steps for the NUV-868 program, including further development in combination with approved products for indications in which BD2-selective BET inhibitors may improve outcomes for patients. Currently, the drug is in the Phase I/II stage of its development for the treatment of Triple Negative Breast Cancer.

• TUB-030: Tubulis

TUB-030 is an antibody drug conjugate directed against 5T4, an oncofetal antigen, expressed in a broad range of solid tumor types. It consists of an IgG1 antibody targeting 5T4 connected to the Topoisomerase I inhibitor exatecan through a cleavable linker system based on the company’s proprietary P5 conjugation technology with a homogeneous DAR of 8. P5 conjugation is a novel chemistry for cysteine-selective conjugation that enables ADC generation with unprecedented linker stability and biophysical properties. Currently the drug is in Preclinical stage of its development for the treatment of TNBC.

The Triple Negative Breast Cancer Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.
• Triple Negative Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market

Explore groundbreaking therapies and clinical trials in the Triple Negative Breast Cancer Pipeline @ New Triple Negative Breast Cancer Drugs

Triple Negative Breast Cancer Companies

Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Triple Negative Breast Cancer Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Triple Negative Breast Cancer Treatment @ Triple Negative Breast Cancer Market Drivers and Barriers

Scope of the Triple Negative Breast Cancer Pipeline Report

• Coverage- Global
• Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
• Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
• Triple Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Triple Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Triple Negative Breast Cancer Therapies and clinical trials @ Triple Negative Breast Cancer Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Triple Negative Breast Cancer Executive Summary
3. Triple Negative Breast Cancer: Overview
4. Triple Negative Breast Cancer Pipeline Therapeutics
5. Triple Negative Breast Cancer Therapeutic Assessment
6. Triple Negative Breast Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Camrelizumab: Jiangsu HengRui Medicine
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. AK117: Akeso Biopharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PMD-026: Phoenix Molecular Designs
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Triple Negative Breast Cancer Companies
18. Triple Negative Breast Cancer Products
19. Triple Negative Breast Cancer Unmet Needs
20. Triple Negative Breast Cancer Market Drivers and Barriers
21. Triple Negative Breast Cancer Future Perspectives and Conclusion
22. Triple Negative Breast Cancer Analyst Views
23. Triple Negative Breast Cancer Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Triple Negative Breast Cancer Clinical Trial Landscape Advances Rapidly as 165+ Companies Innovate in Targeted Biologic Therapies | DelveInsight

DelveInsight’s “Rheumatoid Arthritis Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Rheumatoid Arthritis (RA) pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Rheumatoid Arthritis Pipeline @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

Key Takeaways from the Rheumatoid Arthritis Pipeline Report

• On June 04, 2026- AbbVie initiated a study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide.
• On June 01, 2026- Hoffmann-La Roche highlighted a phase II study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to TNF and/or JAK inhibitors.
• DelveInsight’s Rheumatoid Arthritis Pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Rheumatoid Arthritis treatment.
• The leading Rheumatoid Arthritis Companies such as Gedeon Richter, mAbxience Research S.L., AnaptysBio, Inc, Istesso, Synact Pharma, Sanofi, AstraZeneca, Cullinan Therapeutics, Sonoma Biotherapeutics, Immunovant, Inc, Janssen Research & Development, LLC, Ernexa Therapeutics Inc., Kymera Therapeutics, Inc., Eli Lilly and Company, Rise Therapeutics LLC, Artiva Biotherapeutics, Inc., SinoMab BioScience Limited, ECM Therapeutics, Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing VDJBio Co., LTD., AbbVie, ILAb Co., Ltd., Sonoma Biotherapeutics, Inc., Gilead Sciences, Zenas BioPharma (USA), LLC, Flerie AB, Spyre Therapeutics, Inc, Candid Therapeutics, Inc., LAPIX Therapeutics and others.
• Promising Rheumatoid Arthritis Pipeline Therapies such as BMS-582949, Etanercept, Lutikizumab, Ravagalimab, Filgotinib Maleate, IMVT-1402, TLL-018, CPL409116, LY3541860 and others.

Get insights into clinical trials, emerging therapies, and leading companies with Rheumatoid Arthritis @ Rheumatoid Arthritis Treatment Drugs

The Rheumatoid Arthritis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Rheumatoid Arthritis Pipeline Report also highlights the unmet needs with respect to the Rheumatoid Arthritis.

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disorder primarily affecting synovial joints, often starting symmetrically in small peripheral joints and progressing to larger joints if left untreated. It results from a complex interaction between genetic predisposition and environmental factors such as smoking. RA leads to persistent inflammation, joint destruction, cartilage loss, and bone erosion, contributing to long-term disability and increased mortality if not adequately managed. The disease is classified as early RA when symptoms last fewer than six months, and as established RA when they persist longer. Diagnosis can be challenging due to the lack of a definitive laboratory test, necessitating a comprehensive clinical evaluation. Management includes both pharmacological interventions, particularly early use of disease-modifying anti-rheumatic drugs (DMARDs), and non-pharmacological strategies like physical therapy, counseling, and patient education to reduce morbidity and enhance quality of life.

Rheumatoid Arthritis Emerging Drugs Profile

• RGB-19: Gedeon Richter

RGB-19, developed by Gedeon Richter in collaboration with Mochida Pharmaceutical, is a biosimilar version of tocilizumab, a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling, which plays a central role in the inflammation associated with rheumatoid arthritis. By targeting IL-6, RGB-19 aims to reduce inflammation and alleviate symptoms in patients with rheumatoid arthritis and other immune-mediated conditions. As a biosimilar to the reference product RoActemra®, RGB-19 is designed to offer comparable efficacy and safety, while providing a more affordable therapeutic option to patients worldwide, thereby expanding access to this important biological treatmentCurrently, the drug is registered for the treatment of Rheumatoid Arthritis (RA).

• MB04: mAbxience Research S.L.

MB04, developed by mAbxience Research S.L., is a biosimilar to etanercept designed for the treatment of rheumatoid arthritis and other autoimmune diseases. It is an Fc fusion protein that targets and inhibits both tumor necrosis factor alpha (TNF-α) and lymphotoxin alpha (LTα, also known as TNF-β), key cytokines involved in the inflammatory processes underlying rheumatoid arthritis. By blocking these cytokines, MB04 aims to reduce inflammation and alleviate symptoms associated with immune-mediated joint damage. As a biosimilar, MB04 is intended to offer comparable efficacy and safety to the reference biologic (Enbrel®), while potentially improving access and affordability for patients requiring long-term management of rheumatoid arthritis. Currently, the drug is in Phase III stage of its development for the treatment of Rheumatoid Arthritis (RA).

• Rosnilimab: AnaptysBio, Inc

Rosnilimab is a novel therapeutic antibody that directly targets PD-1, a co-inhibitory receptor preferentially expressed on the surface of activated T cells, which broadly impacts the pathogenic drivers of inflammatory diseases such as RA and UC. Rosnilimab is a targeted therapy designed to deplete PD-1high T cells and agonize the remaining PD-1+ T cells to restore the immune system back to a state of homeostasis. This is anticipated to result in specific immunological outcomes in both inflamed tissue and the periphery, such as reduction in T cell proliferation, migration and cytokine secretion, and reduction of plasma cell generation and autoantibody levels. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis (RA).

• Leramistat: Istesso

Leramistat is an oral treatment that selectively modulates inflammation at the level of tissue damage, adapting to stimulus strength. By avoiding outright inhibition of inflammatory cytokine cascades and promoting a pro-repair environment, leramistat fine-tunes control of subclinical inflammation and restores normal bone dynamics to resolve rheumatoid pathology at its source. With its unique “pro-repair” mechanism, leramistat offers a new foundational option for combination therapy, enabling other disease-modifying treatments to work better for longer and elevating the definition of remission. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis (RA).

• AP1189: Synact Pharma

SynAct Pharma’s drug candidate, resomelagon (AP1189), is a once-daily oral biased melanocortin receptor type 1 and 3 (MC1r and MC3r) agonist. The pharmacological effects of the compound are mediated by its ability to balance ongoing inflammation and bringing the immune system in a given inflamed tissue, organ, or circulation to a new homeostatic state with less proinflammatory activity and activation of pro-resolving pathways. This effect is distinct from suppression of the immune system, which may cause unwanted side effects, such as increased risk of infections and other side effects. The mode of action is specifically interesting to apply in active inflammation, including early active states of chronic inflammatory/autoimmune diseases and in hyperinflammatory states of infectious diseases where the benefit of applying immunosuppressive drugs is outweighed by the risk of use. The selectivity of resomelagon (AP1189) to MC1r and MC3r means that MC2r mediated glucocorticoid release from the adrenal gland is avoided. Thus, the compound induces its pharmacological effects in a steroid-free manner without the significant safety, tolerability, and side effect issues associated with adrenocorticotropic hormone (ACTH) based therapies. Further to that, the compound stimulates the MC1r through biased agonism, activating an alternative pathway, so the compound can be given without the unwanted side effect of skin hyperpigmentation that classical MC1r agonists will induce though cAMP activation in melanocytes. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis (RA).

• LPX-TI641: LAPIX Therapeutics

LPX-TI641 is an oral, small-molecule designed to bind the phosphatidylserine binding pocket on the T cell/transmembrane, immunoglobulin, and mucin (Tim) family of receptors. It is currently under clinical development for autoimmune indications such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and multiple sclerosis with plans to expand to other autoimmune indications where the underlying pathology involves immune imbalances and loss of self-tolerance. LPX-TI641’s primary pharmacology works to restore the adaptive immune system’s self-tolerance rather than suppressing immunity, enabling patients to more effectively and gently combat autoimmune disease. Toxicological studies and emerging clinical data show that LPX-TI641 does not induce neutropenia or lymphocytopenia, suggesting a potentially improved safety profile compared to current therapies. Currently, the drug is in Phase I stage of its development for the treatment of Rheumatoid Arthritis (RA).

Explore groundbreaking therapies and clinical trials in the Rheumatoid Arthritis Pipeline @ New Rheumatoid Arthritis Drugs

The Rheumatoid Arthritis Pipeline Report Provides Insights into-

• l

Rheumatoid Arthritis Companies

Gedeon Richter, mAbxience Research S.L., AnaptysBio, Inc, Istesso, Synact Pharma, Sanofi, AstraZeneca, Cullinan Therapeutics, Sonoma Biotherapeutics, Immunovant, Inc, Janssen Research & Development, LLC, Ernexa Therapeutics Inc., Kymera Therapeutics, Inc., Eli Lilly and Company, Rise Therapeutics LLC, Artiva Biotherapeutics, Inc., SinoMab BioScience Limited, ECM Therapeutics, Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing VDJBio Co., LTD., AbbVie, ILAb Co., Ltd., Sonoma Biotherapeutics, Inc., Gilead Sciences, Zenas BioPharma (USA), LLC, Flerie AB, Spyre Therapeutics, Inc, Candid Therapeutics, Inc., LAPIX Therapeutics and others.

Rheumatoid Arthritis (RA) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Rheumatoid Arthritis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, Rheumatoid Arthritis Pipeline developments, and key companies with DelveInsight’s expert analysis @ Rheumatoid Arthritis Market Drivers and Barriers

Scope of the Rheumatoid Arthritis Pipeline Report

• Coverage- Global
• Rheumatoid Arthritis Companies- Gedeon Richter, mAbxience Research S.L., AnaptysBio, Inc, Istesso, Synact Pharma, Sanofi, AstraZeneca, Cullinan Therapeutics, Sonoma Biotherapeutics, Immunovant, Inc, Janssen Research & Development, LLC, Ernexa Therapeutics Inc., Kymera Therapeutics, Inc., Eli Lilly and Company, Rise Therapeutics LLC, Artiva Biotherapeutics, Inc., SinoMab BioScience Limited, ECM Therapeutics, Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing VDJBio Co., LTD., AbbVie, ILAb Co., Ltd., Sonoma Biotherapeutics, Inc., Gilead Sciences, Zenas BioPharma (USA), LLC, Flerie AB, Spyre Therapeutics, Inc, Candid Therapeutics, Inc., LAPIX Therapeutics and others.
• Rheumatoid Arthritis Pipeline Therapies- BMS-582949, Etanercept, Lutikizumab, Ravagalimab, Filgotinib Maleate, IMVT-1402, TLL-018, CPL409116, LY3541860 and others.
• Rheumatoid Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Rheumatoid Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Rheumatoid Arthritis Pipeline Therapies and clinical trials @ Rheumatoid Arthritis Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Rheumatoid Arthritis (RA): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Rheumatoid Arthritis (RA)– DelveInsight’s Analytical Perspective
7. Late Stage Products (Registration)
8. RGB-19: Gedeon Richter
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. AP1189: Synact Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. LPX-TI641: LAPIX Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Rheumatoid Arthritis (RA) Key Companies
21. Rheumatoid Arthritis (RA) Key Products
22. Rheumatoid Arthritis (RA)- Unmet Needs
23. Rheumatoid Arthritis (RA)- Market Drivers and Barriers
24. Rheumatoid Arthritis (RA)- Future Perspectives and Conclusion
25. Rheumatoid Arthritis (RA) Analyst Views
26. Rheumatoid Arthritis (RA) Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rheumatoid Arthritis Pipeline Shows Strong Momentum as 75+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Psoriasis Pipeline Insight, 2026” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Learn more about our innovative Psoriasis Pipeline today! @ https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight

Key Takeaways from the Psoriasis Pipeline Report

• On June 03, 2026- Haisco Pharmaceutical Group Co., Ltd. initiated a phase I/II clinical study aims to comprehensively evaluate HSK44459 cream’s potential as a treatment for plaque psoriasis, while also characterizing its safety, tolerability, and PK properties in both healthy individuals and patient populations.
• On June 03, 2026- Bristol-Myers Squibb highlighted a study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
• DelveInsight’s Psoriasis pipeline report depicts a robust space with 65+ active players working to develop 75+ pipeline therapies for Psoriasis treatment.
• The leading Psoriasis Companies such as Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.
• Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ-151 cream 0.3%, MP1032, Risankizumab, Certolizumab Pegol, and others.

Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders care @ Psoriasis Clinical Trials Assessment

Psoriasis Overview

Psoriasis is a chronic, inflammatory skin disorder characterized by the rapid buildup of skin cells, leading to red, scaly patches commonly found on the elbows, knees, scalp, and back. This condition is driven by an overactive immune response that accelerates skin cell production, creating raised, itchy plaques. While the exact cause remains unknown, genetics, immune system dysfunction, and environmental triggers such as stress, infections, or injuries play significant roles. Psoriasis can range from mild to severe, impacting quality of life and often associated with other health issues like psoriatic arthritis, cardiovascular disease, and mental health challenges.

Psoriasis Emerging Drugs Profile

• Piclidenoson: Can-Fite Biopharma

Piclidenoson, generically known as IB-MECA (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide), is an oral small molecule drug formulated in a tablet. Piclidenoson mechanism of action is A3AR mediated and includes modulation of key signaling proteins, such as PI3K, PKA, PKB/Akt, IKK and NF-kB, resulting in de-regulation of the Wnt/β-catenin pathway and inhibition of inflammatory cytokine production. Currently, the drug is in Phase III stage of its development for the treatment of Psoriasis. 

• Sonelokimab: MoonLake Immunotherapeutics

Sonelokimab is an investigational Nanobody® developed by MoonLake Immunotherapeutics for treating inflammatory diseases. It targets IL-17A and IL-17F cytokines, inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers, and includes a domain that binds to human albumin to enhance tissue penetration . In Phase 2 trials, sonelokimab demonstrated superior efficacy compared to AbbVie’s Humira in psoriatic arthritis, with higher percentages of patients achieving significant improvements in joint swelling and psoriasis severity . Additionally, it showed promising results in treating hidradenitis suppurativa, meeting the HiSCR75 endpoint in the Phase 2 MIRA trial. Currently, MoonLake is conducting Phase III trials for both conditions and exploring its use in other inflammatory diseases such as palmoplantar pustulosis and axial spondyloarthritis.

• QY101: E-nitiate Biopharmaceuticals

QY101 is a topical ointment developed by E-nitiate Biopharmaceuticals for treating inflammatory skin conditions like atopic dermatitis and plaque psoriasis. It functions as a non-steroidal, non-hormonal phosphodiesterase 4 (PDE4) inhibitor, aiming to reduce inflammation by targeting overactive PDE4 pathways. Preclinical studies have demonstrated favorable pharmacokinetics, strong efficacy, and high safety, making it suitable for various age groups, including children. Currently, QY101 is undergoing a Phase II clinical trial in China for plaque psoriasis, following the completion of a Phase I trial in healthy volunteers. The company is also exploring additional formulations, such as an inhaler, through licensing collaborations.

• SFA 002: SFA Therapeutics

SFA-002, an IL-10 up-regulator in immune cells, is approaching Phase 2 clinical trials and has shown promising Phase 1a and Phase Ib results for the treatment of psoriasis. SFA-002 met its primary endpoint of safety in the Phase 1b clinical trial. No treatment related adverse events or toxicities were observed during the treatment period, and no rebound effects were observed. SFA Therapeutics has filed its annual safety update with the U.S. Food and Drug Administration. SFA-002 met its exploratory endpoint of efficacy. Patients administered SFA-002 demonstrated statistically significant Psoriasis Area and Severity Index (PASI) percentage change and Investigator Global Assessment (IGA) score improvements compared to placebo. PASI is a tool used to measure the severity and extent of psoriasis while IGA is a standardized rating system of patient disease severity. The study was designed in two cohorts, to evaluate two different formulations. Currently the drug is in Phase II/III stage of its development for the treatment of Psoriasis.

• RLS-1496: Rubedo Life Sciences, Inc

RLS-1496 is a first-in-class GPX4 modulator that targets aging cells and surrounding tissues being developed by Rubedo Life Sciences for the treatment of dermatological conditions and other chronic age-related diseases. It is a topical medicine designed to target aging cells, specifically senescent cells, in skin lesions of chronic atopic dermatitis and chronic psoriasis. Currently the drug is in Preclinical stage of its development for the treatment of Psoriasis.

The Psoriasis Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Psoriasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment.
• Psoriasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market.

Learn more about Psoriasis Drugs opportunities in our groundbreaking Research projects @ Psoriasis Unmet Needs

Psoriasis Companies

Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.

Psoriasis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Psoriasis Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Stay informed about how we’re transforming the future of Immunological and Autoimmune Disorders @ Psoriasis Market Drivers and Barriers, and Future Perspectives

Scope of the Psoriasis Pipeline Report

• Coverage- Global
• Psoriasis Companies- Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.
• Psoriasis Pipeline Therapies- Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ-151 cream 0.3%, MP1032, Risankizumab, Certolizumab Pegol, and others.
• Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Psoriasis Pipeline on our website @ Psoriasis Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Psoriasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Psoriasis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Piclidenoson: Can-Fite Biopharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. SFA 002: SFA Therapeutics
12. Early Stage Products (Phase I/II)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. RLS-1496: Rubedo Life Sciences, Inc
17. Inactive Products
18. Psoriasis Key Companies
19. Psoriasis Key Products
20. Psoriasis- Unmet Needs
21. Psoriasis- Market Drivers and Barriers
22. Psoriasis- Future Perspectives and Conclusion
23. Psoriasis Analyst Views
24. Psoriasis Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/psoriasis-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psoriasis Pipeline Expands as 65+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Myelofibrosis Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Myelofibrosis Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight

Key Takeaways from the Myelofibrosis Pipeline Report

• On June 04, 2026, Novartis Pharmaceuticals initiated a phase 3 trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.
• On June 02, 2026, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. highlighted a Phase II Clinical Trial of TQ05105 Tablets Versus Hydroxyurea Tablets in the Treatment of Moderate and High Risk Myelofibrosis.
• DelveInsight’s Myelofibrosis pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for Myelofibrosis treatment.
• The leading Myelofibrosis Companies such as PharmaEssentia Corporation, iOnctura, Prelude Therapeutics, Cellenkos, Ajax Therapeutics, Eilean Therapeutics, Phoenix Molecular Designs, Ryvu Therapeutics, Disc Medicine, Sumitomo Pharma, CERo Therapeutics, Stemline Therapeutics, Incyte Corporation, Takeda, Syntara Limited, Opna Bio, Epigenetix, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GluBio Therapeutics, Telios Pharma, Inc. and others.
• Promising Myelofibrosis Therapies such as Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.

Access DelveInsight’s in-depth Myelofibrosis Pipeline Analysis for a closer look at promising breakthroughs @ Myelofibrosis Clinical Trials and Studies

Myelofibrosis Overview

Myelofibrosis is a chronic blood cancer in which clonal abnormalities in hematopoietic stem cells drive progressive bone marrow fibrosis, resulting in ineffective blood cell production and clinical features such as anemia, splenomegaly, and fatigue. It is classified as a BCR-ABL1–negative myeloproliferative neoplasm and may arise de novo or evolve from antecedent conditions like polycythemia vera or essential thrombocythemia. The disease is strongly associated with driver mutations in JAK2, CALR, or MPL, which lead to persistent activation of the JAK-STAT signaling pathway and a pro-inflammatory cytokine milieu.

Myelofibrosis Emerging Drugs

• Ropeginterferon alfa-2b: PharmaEssentia Corporation

Ropeginterferon alfa-2b is a long-acting, mono-pegylated interferon designed for sustained activation of interferon signaling with improved tolerability and convenient dosing compared to earlier interferons. It exerts antiproliferative and immunomodulatory effects, helping to suppress malignant hematopoietic clones and restore more normal bone marrow function. The drug is currently being studied in a Phase III clinical trial for the treatment of Myelofibrosis.

• Roginolisib: iOnctura

Roginolisib is an orally available, first-in-class allosteric modulator of PI3Kδ, distinguished by its unique binding mode that alters the protein’s 3D conformation and selectively inhibits its activity. By targeting the PI3Kδ isoform commonly dysregulated in cancers and expressed in immunosuppressive cells, it aims to reverse tumor-associated immune suppression while directly inhibing malignant cell proliferation. In myelofibrosis, Roginolisib may help counteract immune-mediated resistance mechanisms that limit current therapies. It is currently being evaluated in a Phase II clinical trial for the treatment of Myelofibrosis.

• RVU120: Ryvu Therapeutics

RVU120 is an oral, selective inhibitor of CDK8 and CDK19, key regulators of transcriptional pathways involved in oncogenesis and inflammation. In Myelofibrosis, it modulates aberrant signaling such as STAT-driven pathways, helping to suppress malignant hematopoietic cell proliferation. The drug has demonstrated potential disease-modifying activity, including reduction of inflammatory cytokines and fibrosis-associated signaling. RVU120 is currently in Phase II of its clinical development, with early studies indicating activity in patients resistant or refractory to JAK inhibitor therapies.

• PRT12396: Prelude Therapeutics

PRT12396 is a mutant-selective JAK2V617F inhibitor being developed for the treatment of patients with certain myeloproliferative neoplasms (MPNs). It has received Investigational New Drug (IND) clearance from the US Food and Drug Administration, enabling clinical evaluation in advanced malignancies, including hematologic cancers. It is currently being evaluated in a Phase I clinical trial for the treatment of Myelofibrosis.

The Myelofibrosis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.
• Myelofibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.

Explore DelveInsight’s expert-driven report today! @ Myelofibrosis Unmet Needs

Myelofibrosis Companies

PharmaEssentia Corporation, iOnctura, Prelude Therapeutics, Cellenkos, Ajax Therapeutics, Eilean Therapeutics, Phoenix Molecular Designs, Ryvu Therapeutics, Disc Medicine, Sumitomo Pharma, CERo Therapeutics, Stemline Therapeutics, Incyte Corporation, Takeda, Syntara Limited, Opna Bio, Epigenetix, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GluBio Therapeutics, Telios Pharma, Inc. and others.

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Myelofibrosis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Myelofibrosis Therapies @ Myelofibrosis Market Drivers and Barriers, and Future Perspectives

Scope of the Myelofibrosis Pipeline Report

• Coverage- Global
• Myelofibrosis Companies- PharmaEssentia Corporation, iOnctura, Prelude Therapeutics, Cellenkos, Ajax Therapeutics, Eilean Therapeutics, Phoenix Molecular Designs, Ryvu Therapeutics, Disc Medicine, Sumitomo Pharma, CERo Therapeutics, Stemline Therapeutics, Incyte Corporation, Takeda, Syntara Limited, Opna Bio, Epigenetix, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GluBio Therapeutics, Telios Pharma, Inc. and others.
• Myelofibrosis Therapies- Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.
• Myelofibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myelofibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive Myelofibrosis Pipeline Report @ Myelofibrosis Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. Myelofibrosis: Overview
4. Myelofibrosis Pipeline Therapeutics
5. Myelofibrosis Therapeutic Assessment
6. Myelofibrosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Ropeginterferon alfa-2b: PharmaEssentia Corporation
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Roginolisib: iOnctura
12. Drug profiles in the detailed report…..
13. PRT12396: Prelude Therapeutics
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Myelofibrosis Key Companies
20. Myelofibrosis Key Products
21. Myelofibrosis- Unmet Needs
22. Myelofibrosis- Market Drivers and Barriers
23. Myelofibrosis- Future Perspectives and Conclusion
24. Myelofibrosis Analyst Views
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/myelofibrosis-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myelofibrosis Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Hidradenitis Suppurativa Pipeline Insight 2026” report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the Hidradenitis Suppurativa Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hidradenitis Suppurativa pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Hidradenitis Suppurativa Treatment Landscape. Click here to read more @ https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-pipeline-insight

Key Takeaways from the Hidradenitis Suppurativa Pipeline Report

• On June 03, 2026- Novartis Pharmaceuticals initiated a study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe hidradenitis suppurativa (HS).
• On June 03, 2026- AbbVie highlighted a study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with the signs and symptoms of moderate to severe HS. Lutikizumab is an investigational drug being developed for the treatment of HS. During Period 1 of the study, participants will placed in 1 of 2 groups called treatment arms. There is a 1 in 2 chance that participants will be assigned to placebo.
• On June 01, 2026- Incyte Corporation announced a phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib.
• DelveInsight’s Hidradenitis Suppurativa pipeline report depicts a robust space with 24+ active players working to develop 24+ pipeline therapies for Hidradenitis Suppurativa treatment.
• The leading Hidradenitis Suppurativa Companies such as InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, and Azora Therapeutics and others.
• Promising Hidradenitis Suppurativa Pipeline Therapies such as Remibrutinib Dose A, AVTX-009, Izokibep, Bimekizumab, Sonelokimab (M1095), Adalimumab and others.

Gain in-depth knowledge of key Hidradenitis Suppurativa Emerging Therapies @ Hidradenitis Suppurativa Clinical Trials Assessment

Hidradenitis Suppurativa Overview

Hidradenitis suppurativa (HS), also called acne inversus, is a chronic inflammatory skin condition with lesions including deep-seated nodules and abscesses, draining tracts, and fibrotic scars. These lesions most commonly occur in intertriginous areas and areas rich in apocrine glands. Among the most common are axillary, groin, perianal, perineal, and inframammary locations. This activity reviews the cause, presentation, and complications of Hidradenitis suppurativa and highlights the role of the interprofessional team in its management. The pathologic process of HS begins when a defective hair follicle becomes occluded and ruptures, spilling its contents, including keratin and bacteria, into the surrounding dermis. A chemotactic inflammatory response by surrounding neutrophils and lymphocytes can lead to abscess formation and subsequent destruction of the pilosebaceous unit and other adjacent structures. Prognosis is variable. There is no cure for this condition. The prognosis worsens if there is a delay in diagnosis and treatment during the early stages of the disease, and also if comorbid conditions of smoking and obesity (if present) are not addressed and improved.

Hidradenitis Suppurativa Emerging Drugs Profile

• Vilobelimab: InflaRx

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. Vilobelimab has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. Vilobelimab is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Approximately 300 people have been treated with vilobelimab in clinical trials, and the antibody has been shown to be well tolerated. Vilobelimab is currently being developed for various indications, including Hidradenitis Suppurativa, ANCA-associated vasculitis, Pyoderma Gangraenosum, cancer and severe COVID‑19. 

• Secukinumab: Novartis

Secukinumab is the first and only fully human biologic that directly inhibits interleukin-17A (IL-17A), an important cytokine involved in the inflammation of psoriatic arthritis (PsA), moderate to severe plaque psoriasis, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)12,13. Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 5 years of clinical data in adults supporting long-term safety and efficacy across moderate to severe plaque psoriasis, PsA and AS14-20. These data strengthen the position of Cosentyx as a treatment across AS, nr-axSpA, PsA and moderate to severe plaque psoriasis, supported by more than 500,000 patients treated worldwide since launch in 2015.

• Avacopan: ChemoCentryx

Avacopan, approved by the FDA as an adjunctive treatment of ANCA-associated vasculitis, is a first-in-class, orally-administered small molecule that employs a novel, highly targeted mode of action in complement-driven autoimmune and inflammatory diseases. While the precise mechanism in ANCA vasculitis has not been definitively established, Avacopan, by blocking the complement 5a receptor (C5aR) for the pro-inflammatory complement system fragment known as C5a on destructive inflammatory cells such as blood neutrophils, is presumed to arrest the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA vasculitis. Avacopan’s selective inhibition of only the C5aR leaves the beneficial C5a pathway through the C5L2 receptor functioning normally. ChemoCentryx is also developing TAVNEOS for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS) and Lupus Nephritis (LN).

• Imsidolimab: AnaptysBio

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.

• Spesolimab: Boehringer Ingelheim

Spesolimab is a novel, humanized, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogeneses of several autoimmune diseases, including GPP. Spesolimab is also under investigation for the prevention of GPP flares and for the treatment of other neutrophilic skin diseases, such as palmoplantar pustulosis (PPP) and hidradenitis suppurativa (HS).

Hidradenitis Suppurativa Market Drivers

• Advancements in Research and Development
• Rise in awareness about the disease

Hidradenitis Suppurativa Market Barriers

• Stigma and Patient Reluctance
• Complexity of the disease

The Hidradenitis Suppurativa Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hidradenitis Suppurativa with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hidradenitis Suppurativa Treatment.
• Hidradenitis Suppurativa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hidradenitis Suppurativa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hidradenitis Suppurativa market

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hidradenitis Suppurativa Unmet Needs

Hidradenitis Suppurativa Companies

InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, and Azora Therapeutics and others.

Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Hidradenitis Suppurativa Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

See the latest progress in drug development and clinical research @ Hidradenitis Suppurativa Market Drivers and Barriers, and Future Perspectives

Scope of the Hidradenitis Suppurativa Pipeline Report

• Coverage- Global
• Hidradenitis Suppurativa Companies- InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, Azora Therapeutics and others.
• Hidradenitis Suppurativa Pipeline Therapies- Remibrutinib Dose A, AVTX-009, Izokibep, Bimekizumab, Sonelokimab (M1095), Adalimumab and others.
• Hidradenitis Suppurativa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hidradenitis Suppurativa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Hidradenitis Suppurativa Pipeline Analysis Today! @ Hidradenitis Suppurativa Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Hidradenitis Suppurativa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hidradenitis Suppurativa – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Vilobelimab: InflaRx
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Spesolimab: Boehringer Ingelheim
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. AT193: Azora Therapeutics
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Hidradenitis Suppurativa Key Companies
24. Hidradenitis Suppurativa Key Products
25. Hidradenitis Suppurativa – Unmet Needs
26. Hidradenitis Suppurativa – Market Drivers and Barriers
27. Hidradenitis Suppurativa – Future Perspectives and Conclusion
28. Hidradenitis Suppurativa Analyst Views
29. Hidradenitis Suppurativa Key Companies
30. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hidradenitis-suppurativa-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hidradenitis Suppurativa Pipeline Gains Momentum: 24+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Obstructive Sleep Apnea Pipeline Insight 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Obstructive Sleep Apnea pipeline landscape. It covers the Obstructive Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obstructive Sleep Apnea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Obstructive Sleep Apnea Pipeline? @ https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight

Key Takeaways from the Obstructive Sleep Apnea Pipeline Report

• On June 04, 2026- Amgen conducted a Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.
• On June 04, 2026- Eli Lilly and Company announced a phase 3 studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.
• On June 02, 2026- Novo Nordisk A/S initiated a study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.
• DelveInsight’s Obstructive Sleep Apnea Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Obstructive Sleep Apnea treatment.
• The leading Obstructive Sleep Apnea Companies such as Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, Desitin Arzneimittel GmbH, Shionogi Apnimed Sleep Science and others.
• Promising Obstructive Sleep Apnea Therapies such as Sulthiame, AD128, Mannitol, AD313, AVE0657, Eszopiclone, BAY2586116, Atomoxetine, BAY2253651, AD504, Atomoxetine, R-oxybutynin and others.

Want to know which companies are leading innovation in Obstructive Sleep Apnea? @ Obstructive Sleep Apnea Clinical Trials Assessment

The Obstructive Sleep Apnea Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Obstructive Sleep Apnea Pipeline Report also highlights the unmet needs with respect to the Obstructive Sleep Apnea.

Obstructive Sleep Apnea Overview

Obstructive Sleep Apnea (OSA) is a common sleep-related breathing disorder characterized by repeated partial or complete obstruction of the upper airway during sleep. This obstruction leads to disrupted airflow despite ongoing respiratory effort, causing shallow breathing (hypopnea) or brief pauses in breathing (apnea). As a result, oxygen levels may drop, and the body responds by briefly awakening the individual, often with a gasp, snort, or sudden movement. OSA is frequently associated with loud snoring and fragmented, non-restorative sleep. Common symptoms include excessive daytime sleepiness, morning headaches, dry mouth or sore throat, difficulty concentrating, mood changes, night sweats, restless sleep, and may also be linked to Gastroesophageal Reflux Disease (GERD).

Obstructive Sleep Apnea Emerging Drugs Profile

• AD109: Apnimed

AD109 is an investigational, once-daily oral therapy being developed for the treatment of Obstructive Sleep Apnea (OSA), targeting the neuromuscular mechanisms responsible for upper airway collapse during sleep. It acts on the Hypoglossal Motor Nucleus to enhance upper airway dilator muscle activity, thereby helping maintain airway patency and improving oxygen levels. This first-in-class anti-apneic neuromuscular modulator combines aroxybutynin (an antimuscarinic agent) and atomoxetine (a selective norepinephrine reuptake inhibitor) to achieve synergistic therapeutic effects. Designed as a convenient bedtime pill, AD109 is currently under Phase III clinical evaluation as a non-invasive treatment option for patients with mild to severe OSA.

• HRS9531: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

HRS9531 is an investigational therapeutic agent being explored for the treatment of Obstructive Sleep Apnea (OSA), with a focus on addressing underlying metabolic and physiological contributors to the condition. It is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist designed to promote weight loss and improve metabolic health, which are key factors in OSA severity. By reducing body weight and potentially decreasing upper airway obstruction, HRS9531 may help improve breathing patterns during sleep. Currently, the drug is under Phase III clinical evaluation for the treatment of OSA.

If you’re tracking ongoing Obstructive Sleep Apnea Clinical trials, this press release is a must-read @ Obstructive Sleep Apnea Treatment Drugs

The Obstructive Sleep Apnea Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Obstructive Sleep Apnea with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obstructive Sleep Apnea Treatment.
• Obstructive Sleep Apnea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Obstructive Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obstructive Sleep Apnea market.

Obstructive Sleep Apnea Companies

Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, Desitin Arzneimittel GmbH, Shionogi Apnimed Sleep Science and others.

Obstructive Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Obstructive Sleep Apnea Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Obstructive Sleep Apnea Pipeline Report covers it all @ Obstructive Sleep Apnea Market Drivers and Barriers, and Future Perspectives

Scope of the Obstructive Sleep Apnea Pipeline Report

• Coverage- Global
• Obstructive Sleep Apnea Companies- Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, Desitin Arzneimittel GmbH, Shionogi Apnimed Sleep Science and others.
• Obstructive Sleep Apnea Therapies- Sulthiame, AD128, Mannitol, AD313, AVE0657, Eszopiclone, BAY2586116, Atomoxetine, BAY2253651, AD504, Atomoxetine, R-oxybutynin and others.
• Obstructive Sleep Apnea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Obstructive Sleep Apnea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Obstructive Sleep Apnea Treatment landscape in this detailed analysis @ Obstructive Sleep Apnea Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Obstructive Sleep Apnea: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Obstructive Sleep Apnea (OSA)– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. AD109: Apnimed
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. MOS118: Mosanna Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Obstructive Sleep Apnea Key Companies
21. Obstructive Sleep Apnea Key Products
22. Obstructive Sleep Apnea- Unmet Needs
23. Obstructive Sleep Apnea- Market Drivers and Barriers
24. Obstructive Sleep Apnea- Future Perspectives and Conclusion
25. Obstructive Sleep Apnea Analyst Views
26. Obstructive Sleep Apnea Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obstructive Sleep Apnea Pipeline Shows Potential with Active Contributions from 18+ Key Companies | DelveInsight